Abbott Laboratories Corporation

David P Pacenti

Saul A Datwyler

Shelley R Holets-McCormack

Gangamani S Beligere

Thomas G Spring

Elaine Marie Brate

John M Ramp

David M Finley

Philip P Wang

Melissa B Brennan

Jessica Grieshaber

Ryan E Piktel

Michelle L Shields

Phillip P Wang

Shelley R Holets-Mccormack

Michelle Shields

Disclosed herein are improved methods of processing, measuring, and detecting levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in blood samples taken from a human subject at time points within about 8 hours (or about 8 hours or less) after obtaining the sample from the subject. UCH-L1 is an early biomarker for traumatic brain injury (TBI), and there is a need for improved methods for assessing UCH-L1 in blood can aid in the diagnosis and evaluation of a human subject who has sustained or may have sustained a head injury.

Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood

The present disclosure provides among other things immunoassays exhibiting reduced cross-reactivity with analyte metabolites. Additionally, the present disclosure provides diagnostic immunoassays to determine the concentration or level in a test sample of a hydrophobic drug that metabolizes in vivo or in vitro to form cross-reacting metabolites wherein cross-reactivity with such metabolites of the drug analyte is reduced. In particular, the disclosure provides such immunoassays where the hydrophobic drug is an immunosuppressant drug such as cyclosporine A.

Immunoassays exhibiting reduced cross-reactivity with hydrophobic drug analyte metabolites

Growing community of inventors

Gurnee, IL, United States of America

David P Pacenti